more

STERIS (STE)

(Delayed Data from NYSE)

$236.01 USD

+1.87 (0.80%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $236.04 +0.03 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

Top 32% (81 out of 251)

Industry: Medical - Instruments

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

STERIS (STE) Q2 Earnings & Revenues Beat Estimates, Rise Y/Y

by Zacks Equity Research Published on November 08,2018

STERIS (STE) continues to gain from strength in all business segments in Q2.

medical

Steris (STE) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research Published on November 06,2018

Steris (STE) delivered earnings and revenue surprises of 1.85% and 3.35%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

STEPositive Net Change

Will Steris (STE) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research Published on November 02,2018

Steris (STE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

STEPositive Net Change

Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research Published on October 30,2018

Steris (STE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

STEPositive Net Change

STERIS (STE) Strategic Growth Strong Amid Several Headwinds

by Zacks Equity Research Published on September 28,2018

STERIS (STE) impresses with favorable underlying market trends apart from new products and service offerings. Yet, a severe competition lurking beneath is worrisome for the company.

Why Is Steris (STE) Down 1.2% Since Last Earnings Report?

by Zacks Equity Research Published on September 07,2018

Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

STEPositive Net Change

STERIS (STE) Strategic Growth Strong, Competition a Woe

by Zacks Equity Research Published on August 27,2018

STERIS' (STE) beneficial underlying market trends along with new product and service offerings are impressive. Meanwhile, the company worries over facing a severe competition.

STERIS (STE) Q1 Earnings & Revenues Beat Estimates, Up Y/Y

by Zacks Equity Research Published on August 10,2018

STERIS (STE) continues to gain from strength in all business segments in Q1.

Steris (STE) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research Published on August 08,2018

Steris (STE) delivered earnings and revenue surprises of 2.04% and 0.01%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

STEPositive Net Change

Can Solid European Sales Boost Inogen (INGN) in Q2 Earnings?

by Zacks Equity Research Published on July 30,2018

Strong performance in Europe is likely to boost Inogen's (INGN) top line in Q2. However, decline rental-revenues is a concern.

Intuitive Surgical's FDA Approval for SureForm to Aid Surgery

by Zacks Equity Research Published on July 09,2018

Intuitive Surgical's (ISRG) SureForm 60 stapler receives FDA approval; strengthens its profile for minimally invasive surgical solutions.

MASI or STE: Which Is a Better Investment Option Right Now?

by Zacks Equity Research Published on July 05,2018

Masimo's (MASI) and STERIS' (STE) strong expected growth rates and impressive price performance make them close contenders in the Medical Instruments space.

Here's Why You Must Add STERIS (STE) to Your Portfolio Now

by Zacks Equity Research Published on June 26,2018

STERIS' (STE) acquisition of U.K.-based outsourced sterilization services provider, Synergy Health plc, remains one of its key strategic moves.

Medical Device Firms in Focus on Expanded R&D Scope: 5 Picks

by Zacks Equity Research Published on June 26,2018

The suspension of the Medical Device Tax, the evolution of mechatronics and big data in the MedTech space make some of the stocks lucrative picks for investment.

Mechatronics for Healthcare: 3 MedTech Stocks to Bet On

by Nabaparna Bhattacharya Published on June 20,2018

Here we analyze how Medical Mechatronics is creating new opportunities in MedTech for investors who are keen on putting their money in the healthcare space for longer-term gains.